Evaluation of immune status of malignant pleural mesothelioma patients with peripheral blood mnonuclear cells

Evaluation of immune status of malignant pleural mesothelioma patients with peripheral blood mnonuclear cells - Evaluation of immune status of malignant pleural mesothelioma patients with peripheral blood mnonuclear cells

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034916

Enrollment

Registered

2018-11-16

Start date

2018-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant pleural mesothelioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 20 years or older when acquiring consent 2.Patients who have obtained written consent to the study

Exclusion criteria

Exclusion criteria: 1.Patients judged that the doctor in charge is inappropriate for participation in this study

Design outcomes

Primary

Measure	Time frame
Clarify the relationship between the therapeutic effect of nibormab and pretreatment PBMC analysis.	—

Countries

Japan

Contacts

Public ContactOu Yamaguchi

Saitama Medical University International Medical Center respiratory medicine

ouyamagu@saitama-med.ac.jp042-984-4111

Outcome results